Phase IIA Double-Masked Randomized Sham-Controlled Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Subjects With Acute Primary Angle-Closure Glaucoma (APACG)

Glaucoma, Angle-closure, Primary, Acute Clinical Trial

Official title:

Phase IIA Double-Masked Randomized Sham-Controlled Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Subjects With Acute Primary Angle-Closure Glaucoma (APACG)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01965106
• Other study ID #: QRK208
• Status: Completed
• Phase: Phase 2
• First received: September 11, 2013
• Last updated: April 6, 2017
• Start date: December 2013
• Est. completion date: July 2015

Study information

• Verified date: April 2017
• Source: Quark Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will assess any side effects that may occur when QPI-1007 is injected into the eye in subjects with acute primary angle-closure glaucoma, as well as how long it takes for the body to clear the drug. This study will also test whether QPI-1007, injected into the eye, helps prevent both structural damage of the nerve tissue in the eye and the loss of visual function in subjects with acute primary angle-closure glaucoma.

Description:

This is a Phase IIa double-masked, single dose, randomized, sham-controlled study evaluating the safety and tolerability, and pharmacokinetics of QPI-1007 versus Control (sham procedure) in subjects with an acute attack of primary angle-closure glaucoma.

Subjects will be randomized at a ratio of 1:1 into one of two study arms: 1.5 QPI-1007 arm or Control arm (sham procedure). The study will enroll approximately 30 subjects into each arm. Randomization will be stratified by time from symptom onset to the study drug administration or sham procedure (≤72 hours and >72 hours).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 46
• Est. completion date: July 2015
• Est. primary completion date: June 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• Males and females aged at least 40 years or older.

• Onset of symptoms of an acute attack of primary angle-closure in the study eye within the 120 hours prior to the planned study drug administration.

• Best-corrected visual acuity (BCVA) 20/40 or better in the study eye after resolution of the acute attack.

• Received successful treatment for the acute attack of angle-closure, and have undergone laser iridotomy with intraocular pressure in the study eye <25mm Hg.

• Sufficiently clear ocular media and adequate pupil dilation to allow the optic nerve and fovea to be visualized and assessed in the study eye.

• Female subjects must be: (1) post menopausal, (2) surgically sterile, or (3) using an effective means of contraception.

Exclusion Criteria:

• Previously diagnosed with glaucoma in either eye.

• The time planned for study drug administration is more than 120 hours from the onset of the symptoms.

• History of chronic angle-closure in either eye.

• Secondary angle-closure/secondary angle-closure glaucoma in the study eye.

• Monocular subjects.

• Prior incisional intraocular surgery.

• Inability to perform a reliable visual field test on Day 0 in the study eye.

• History of panretinal photocoagulation or macular laser photocoagulation in the study eye.

• History of active malignancy within the last 5 years (however, non facial, basal cell carcinoma is allowed).

• History of myocardial infarction within the last 6 months.

• Received any drugs known to cause optic nerve or retinal toxicity within 14 days prior to dosing.

• Women who are pregnant or lactating.

• Participating in a concurrent interventional study with the last intervention occurring within 30 days prior to planned dosing with QPI-1007.

Related Conditions & MeSH terms

• Glaucoma
• Glaucoma, Angle-Closure
• Glaucoma, Angle-closure, Primary, Acute

Intervention

Drug:
• QPI-1007 Injection
1.5 mg QPI-1007 Injection
• (including placebo)
Sham injection procedure

Locations

Country	Name	City	State
Singapore	Singapore National Eye Centre	Singapore
United States	Robert Cizik Eye Clinic - Clinical Trials Unit	Houston	Texas
United States	The Gavin Herbert Eye Institute, UC Irvine	Orange	California
United States	Doheny Eye Center, UCLA	Pasadena	California
United States	Dept. of Ophthalmology, University of Washington Medical Center	Seattle	Washington
Vietnam	Hanoi Eye Hospital	Ha Noi
Vietnam	Vietnam National Institute of Ophthalmology	Ha Noi
Vietnam	Ho Chi Minh City Eye Hospital	Ho Chi Minh City

Sponsors (1)

Lead Sponsor	Collaborator
Quark Pharmaceuticals

Countries where clinical trial is conducted

United States,  Vietnam,  Singapore, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and tolerability of a single intravitreal (IVT) dose of QPI-1007 as assessed by adverse events (AE)		Day 0 (after injection) through Month 4. Systemic serious AEs (SAEs) assessed as related to study drug and all ocular SAEs Month 4 to Month 6 after injection
Primary	Safety and tolerability of a single IVT dose of QPI-1007 as assessed by laboratory evaluations		Screening, Day 1, and Month 4 after injection
Primary	Safety and tolerability of a single IVT dose of QPI-1007 as assessed by vital signs and weight		Weight: Screening and Month 4; Vital signs: Screening, Days 0 (before injection), 1 and 7, and Month 4 to 6
Primary	Safety and tolerability of a single IVT dose of QPI-1007 as assessed by ophthalmic evaluations, Best Corrected Visual Acuity (BCVA) using Early Treatment Diabetic Retinopathy Study (EDTRS) chart and slit lamp exams (anterior & posterior segment)		Screening, Days 0, 1 and 7, and Month 1 to 6
Primary	Safety and tolerability of a single IVT dose of QPI-1007 as assessed by ophthalmic evaluations, Visual Field (VF) and Spectral Domain Optical Coherence Tomography (SD-OCT)		Days 0 and 7, and Month 1 to 6
Primary	Safety and tolerability of a single IVT dose of QPI-1007 as assessed by ophthalmic evaluation intraocular pressure (IOP)		Screening, Days 0 (before injection, both eyes; after injection study eye only), 1 and 7, and Month 1 to 6
Primary	Safety and tolerability of a single IVT dose of QPI-1007 as assessed by ophthalmic evaluation, Fundus Photographs (FP)		Days 0 and 7, and Month 4
Primary	Safety and tolerability of a single IVT dose of QPI-1007 as assessed by ophthalmic evaluations optic nerve head stereo photographs and contrast sensitivity		Days 0 and 7, and Month 4 and 6
Primary	Safety and tolerability of a single IVT dose of QPI-1007 as assessed by use of concomitant treatments		Days 0, 1 and 7, and Month 1 to 6
Secondary	QPI-1007 pharmacokinetics (PK) parameters as assessed by the peak plasma concentration (Cmax)		Pre-injection, 1, 4 and 24 hours after injection, and 7 days after injection
Secondary	QPI-1007 pharmacokinetics (PK) parameters as assessed by the time to peak plasma concentration (Tmax)		Pre-injection, 1, 4 and 24 hours after injection, and 7 days after injection
Secondary	Difference between QPI-1007 and control group (sham) as assessed by the prevalence of the abnormal visual fields		4 months after injection
Secondary	Difference between QPI-1007 and control group (sham) as assessed by change in the mean deviation compared to baseline		4 months after injection
Secondary	Difference between QPI-1007 and control group (sham) as assessed by progression of the visual fields compared to baseline		4 months after injection
Secondary	Difference between QPI-1007 and control group (sham) as assessed by change in the mean BCVA using the EDTRS chart compared to baseline		4 months after injection
Secondary	Difference between QPI-1007 and control group (sham) as assessed by SD-OCT parameters		4 months after injection
Secondary	Difference between QPI-1007 and control group (sham) as assessed by change in the mean contrast sensitivity compared to baseline		4 months after injection